Saturday, February 7, 2026 at 10:30 AM
Novo's guidance indicates a potential drop in profits and sales due to pricing pressures in the weight-loss drug market, reflecting the impact of competition and cost-cutting measures.
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
The pharma major said it faces the largest drug-patent expiry headwind in its history this year.
Plus, it’s a big investing world out there
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
Data sourced from public RSS feeds and News APIs.
